ENTRADA THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $99.61M.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $19.41M.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $99.61M, a 413.26% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $19.41M.
- ENTRADA THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $190.69M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $99.61M 10-K · filed 2026-02-26 | |
| 2024-06-30 | $99.61M 10-Q · filed 2025-11-06 | |
| 2023-12-31 | $19.41M 10-K · filed 2025-02-27 | |
| 2023-03-31 | $19.41M 10-Q · filed 2024-11-05 | |
| 2021-12-31 | $190.69M 10-K · filed 2023-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |